Rotavirus Vaccine Market

Global Rotavirus Vaccine Market Size (2024 to 2029)

The global rotavirus vaccine market size is valued at USD 8.34 billion in 2024 and is anticipated to reach USD 11.53 billion by 2029 with a CAGR of 6.7% during the forecast period. 

Rotavirus is commonly caused in babies and younger children with severe watery diarrhea, vomiting, and fever symptoms. In this case, children are dehydrated and need to be hospitalized, and in rare cases, death occurs. Rotavirus vaccine is administered to children by putting drops in the mouth, where they need 2 to 3 doses of vaccine respective to the vaccine brand. The first dose of the vaccine is administered before 15 weeks of age, and the second dose should be administered by eight months of age. Two rotavirus vaccines are currently licensed in the U.S. for infants – RotaTeq, given in three doses before six months of age, and Rotarix, given in two doses before four months of age.

Global Rotavirus Vaccine Market Drivers:

The growing prevalence of the rotavirus disease among children worldwide is majorly contributing to the global rotavirus vaccine market growth. According to UNICEF data, more than 215,000 children under the age of five die annually from rotavirus infections. WHO states that approximately 47 percent of the immunization coverage rate for the rotavirus vaccine reaches children globally. The noticeable number of children not receiving the vaccine is rising. The government initiatives to bring awareness among the people regarding the importance of vaccination and its benefits are boosting the growth of the global rotavirus market value. Countries with poor economic status are witnessing a high death ratio due to rotavirus. The mortality due to the rotavirus across the globe is 600,000 each year, and 80% of these deaths are from less developed countries. The growing investments in the R&D sector for the clinical trials of the vaccines by the significant market players and the increasing government collaborations with the market players are enhancing global market revenue growth. The increasing number of people with weak immune systems is due to their sedentary lifestyle and unbalanced diet. Most of the children and older adults are under malnutrition, which leads to weaker immunity among them, which enhances the chances of being infected by the virus. There is a growing number of older people across various countries where older adults without vaccination are highly prone to the rotavirus. These factors are escalating the growth of global rotavirus vaccine market share. 

The increasing vaccination production in major countries is enhancing the availability of vaccines to more children and older adults, boosting the global market revenue. As there is a growing incidence of rotavirus with severe symptoms such as diarrhea, vomiting, fever, and abdominal pain, the vaccine against the rotavirus is being highly considered in various regions, which is expected to augment the global market growth.

The growing technological advancements in the healthcare industry, growing research activities by the market players, and increasing product availability are expected to augment global market growth during the forecast period. The increasing focus of the researchers on developing vaccinations with minimal adverse reactions is expected to escalate the market growth opportunities in the upcoming years. The growing healthcare expenditures of developing countries will increase the demand for vaccinations, which will enhance the global market share during the forecast period. The suggestions from public authorities like WHO to compulsorily include the rotavirus vaccine in the national vaccine program for countries with high risk of infection with rotavirus. These amendments are estimated to increase the profitable opportunities for the global rotavirus vaccine market.

Global Rotavirus Vaccine Market Restraints:

The major restraining factor is the risks associated with the vaccination, such as allergic reactions, severe combined immunodeficiency, and intussusception. Intussusception is a significant drawback of the rotavirus vaccine, where it is a type of bowel blockage that requires treatment or surgery. It is primarily observed in infants, where the risk of intussusception increases with the rotavirus vaccine's first or second dose. In some cases, allergic reactions such as swelling of the face and throat, difficulty breathing, dizziness, or weakness are expected to occur in older people after the vaccination. All these adverse vaccine reactions are expected to hamper the global rotavirus vaccine expansion. 

The need for more awareness among the various populations of low-economic countries and developing countries is limiting the adoption of vaccination, which is challenging for market expansion. The delayed timelines for the new vaccine manufacturers due to stringent regulations by the regulatory authorities, which are complex and time-consuming, are expected to impede the growth of the global market in the upcoming years.

Impact of Covid-19 on the Rotavirus Vaccine Market:

The Pandemic negatively impacted the rotavirus vaccine market due to the stringent COVID-19 regulations by the government. Due to COVID-19, there are several disruptions in the optimum availability and utilization of immunization services. The Pandemic has led to delays in the production, manufacturing, and distribution of goods to various countries due to disruptions in the supply chain. However, post-COVID, various surveys were conducted to determine the unimmunized and partially immunized children; these were completely immunized after the Pandemic.

Report Coverage:

The global rotavirus vaccine market is segmented and sub-segmented based on the following categories:

Global Rotavirus Vaccine Market - By Type:

• RotaTeq
• Rotarix
• Rotavac
• Rotavin-M1
• Lanzhou Lamb
• Others

The RotaTeq and Rotarix are the two vaccines the U.S. Food and Drug Administration licenses to use in the United States. These two vaccines have the most significant market share compared to other vaccines. Due to their wide adoption among people, global market growth is being noted, and it is estimated that these vaccines will record a significant market value in the forecast period. The primary benefit of these two vaccines was that they were not associated with intussusception and provided more than 70 percent protection against rotavirus diarrhea. These factors all lead to segment growth, enhancing the global rotavirus vaccine market growth.

Global Rotavirus Vaccine Market - By End-Use:

• Hospitals
• Clinics
• Academic & Research Labs

Due to its reliability, the hospital segment dominated the global rotavirus vaccine market revenue. Hospitals are highly equipped with skilled healthcare professionals and technological equipment. Government funding and public authorities support hospitals, which is why they have a greater number of suppliers. Most pharmaceutical companies are partnered with various hospitals, boosting segment growth by enhancing the global rotavirus vaccine market value among the population. 

The clinic's segment has moderate growth in the global market due to increasing separate clinics with medical facilities. 

The Academic and research labs segment is estimated to have prominent growth during the forecast period due to increasing research studies and investments by the market players. 

Global Rotavirus Vaccine Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

North American region dominated the global rotavirus vaccine market due to the presence of major manufacturers in the region. The presence of prominent healthcare infrastructure with advanced technology is inducing growth in research activities, impacting the expansion of the regional market—and increasing the prevalence of infectious diseases, which includes rotavirus among children and infants. The growing older people across the region are highly prone to infectious diseases due to low immunity. All these factors are propelling the global market growth in the North American region. The presence of prominent pharmaceutical companies and vaccine manufacturers in developed countries like the U.S. and Canada is prompting market expansion. Rotavirus gastroenteritis results in only 20 to 70 deaths of children per year in the United States due to the presence of an advanced technological healthcare system in the country.  

The Asia Pacific region is projected to grow significantly during the forecast period with a significant CAGR due to increasing government initiatives to bring awareness among the people and make vaccination compulsory. The growing research activities in countries like China and India induce market share development in the region. The growing population in countries like China, where children count, is increasing the demand for rotavirus vaccinations by enhancing the global market growth. The increasing healthcare expenditure by developing countries is increasing the broad adoption of immunization programs across the world. 

The European region is expected to have a moderate growth rate during the forecast period due to the advanced healthcare system with presence of top pharmaceutical companies. The presence of advanced R&D sectors, which increases the development of safe and efficient vaccines with minimal adverse reactions, is expected to boost the global market revenue in the upcoming years.

Key Market Players:

BIOVIRx Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, Bio Farma, Lanzhou Institute of Biologicals Products Co., GlaxoSmithKline plc., Merck & Co., Berghofer Medical Research Institute, Novartis AG are some of the key market players in the rotavirus vaccine market.

Recent Market Developments:

• In 2021, GSK, a global drug manufacturer, signed a contract with UNICEF to supply its rotavirus, Rotarix, through the Humanitarian Mechanism for civil society organizations. 
• In 2021, Bharat Biotech received the "BioSpectrum Product of the Year Award 2020" for its rotavirus vaccine, ROTAVAC 5D. This vaccine is effective and safe in the prevention of rotavirus diarrhea.